NTRA - ナテラ （Natera Inc.） ナテラNTRAのチャート
NTRAの企業情報
| symbol | NTRA |
|---|---|
| 会社名 | Natera Inc （ナテラ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ナテラ(Natera Inc.)は診断会社である。同社は遺伝子検査サービスの発見・開発・商品化に従事する。同社は、母親から採血した胎児の染色体異常をスクリーニングするパノラマ非侵襲性出生前検査、キャリアの子供に渡される可能性のある多数の重度の遺伝病のキャリアステータスを決定するホライゾンキャリアスクリーニング、体外受精サイクル中に染色体異常または遺伝的遺伝的状態を分析して健康な子供になる可能性のある胚を選択するスペクトラムプレ移植遺伝子スクリーニングとスペクトラムプレ移植遺伝子診断、流産の原因を理解するために胎児の染色体を分析する受胎テストのAnora製品、並びに妊娠している母親の血液中の胎児性デオキシリボ核酸の断片と、疑わしい父親由来の血液サンプルを分析することにより父性を決定する非侵襲性父性検査を提供する。 ナテラは米国の遺伝子検査サ―ビス会社。主に出生前の遺伝子検査を提供する。体外受精において、着床前遺伝子スクリ―ニングを提供し、染色体異常や遺伝性遺伝子の状態を解析することで、受精胚の選択を可能にする。また、胎児の染色体異常を発見する検査や実父確定検査なども提供する。本社はカリフォルニア州サンカルロス。 Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. |
| 本社所在地 | 201 Industrial Road Suite 410 San Carlos CA 94070 USA |
| 代表者氏名 | Matthew Rabinowitz マシュー・ラビノウィッツ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Co-Founder |
| 電話番号 | +1 650-249-9090 |
| 設立年月日 | 37926 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 893人 |
| url | www.natera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ntra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -120.49200 |
| 終値（lastsale） | 21.31 |
| 時価総額（marketcap） | 1298720475.8 |
| 時価総額 | 時価総額（百万ドル） 1225.587 |
| 売上高 | 売上高（百万ドル） 235.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1265.723 |
| 当期純利益 | 当期純利益（百万ドル） -139.31800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Natera Inc revenues increased 23% to $125.4M. Net loss increased 7% to $66.7M. Revenues reflect United States segment increase of 21% to $107M Europe Middle East India Africa segment increase of 91% to $13.1M. Higher net loss reflects Interest and other income decrease from $887K (income) to $3.8M (expense) Interest expense increase from $401K to $4.9M (expense). |
NTRAのテクニカル分析
NTRAのニュース
Prenatal Testing & Newborn Screening Market Research Report 2021 - ResearchAndMarkets.com 2021/07/16 11:35:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Prenatal Testing & Newborn Screening Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The market is expected to reach $8.018 billion in 2025 at a CAGR of 14%. Major players in the prenatal testing and newborn screening tests market are PerkinElmer, Progenity, Laboratory Corporation of America Holdings (Sequenom), Natera, Invitae, Centogene, Cradle Genomics, Roche Diagnostics, Quest Diagno
Natera Inc (NTRA) CEO AND PRESIDENT Steven Leonard Chapman Sold $3.8 million of Shares 2021/07/08 22:15:05 GuruFocus
Related Stocks: NTRA ,
Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value 2021/07/01 09:18:16 Seeking Alpha
This Explosive Biotech Is Taking On a Huge New Market 2021/06/30 15:17:20 The Motley Fool
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Natera Inc (NTRA) CEO AND PRESIDENT Steven Leonard Chapman Sold $3.8 million of Shares 2021/07/08 22:15:05 GuruFocus
Related Stocks: NTRA ,
Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value 2021/07/01 09:18:16 Seeking Alpha
This Explosive Biotech Is Taking On a Huge New Market 2021/06/30 15:17:20 The Motley Fool
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Hedge Funds Arent Crazy About Natera Inc (NTRA) Anymore 2021/06/23 17:12:01 Yahoo Finance
In this article you are going to find out whether hedge funds think Natera Inc (NASDAQ:NTRA) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among []
Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value 2021/07/01 09:18:16 Seeking Alpha
This Explosive Biotech Is Taking On a Huge New Market 2021/06/30 15:17:20 The Motley Fool
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Hedge Funds Arent Crazy About Natera Inc (NTRA) Anymore 2021/06/23 17:12:01 Yahoo Finance
In this article you are going to find out whether hedge funds think Natera Inc (NASDAQ:NTRA) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among []
Analyst Ratings For Natera 2021/06/22 15:50:13 Benzinga
Within the last quarter, Natera (NASDAQ: NTRA ) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 0 Somewhat Bullish 1 3 1 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 9 analysts have offered 12-month price targets for Natera. The company has an average price target of $139.89 with a high of $160.00 and a low of $110.00. This current average represents a 8.44% increase from the previous average price target of $129.0. What Are Full story available on Benzinga.com